Vesugen Peptide (KED): Evidence, Safety and How to Verify It

Research use only. Nothing on this page is medical advice, and Vesugen isn’t approved for human use.

Vesugen is the tripeptide Lys-Glu-Asp (KED), a bioregulator from Vladimir Khavinson’s group, studied as a blood-vessel peptide. Its best results are in cells: in neurons made from elderly donors’ skin it raised total dendrite length by 42%. The only human study had 32 patients, tested it with Pinealon, and also reported prooxidant activity and fewer CD34+ blood stem cells. No independent trial exists and FDA hasn’t approved it.

Sequence

Lys-Glu-Asp (KED), a tripeptide from Vladimir Khavinson’s group

Origin

KED was isolated from calf blood-vessel peptide complexes (9)

Mass and CAS

390.4 g/mol by calculation; CAS 204271-66-9 is the free acid (12)

Claimed target

Blood vessels and, more recently, neurons

Human evidence

One 32-patient study from the same group, with Pinealon (11)

Independent trials

None found (13)

FDA status

Not approved. Not on FDA’s compounding-risk page or in HHS’s October 2026 policy (14, 15)

WADA 2026

S0 catch-all for unapproved substances (16)

What is Vesugen peptide?

Vesugen is the brand name for KED, lysine-glutamate-aspartate, a tripeptide of Khavinson’s cytogens. KED was isolated from polypeptide complexes of calf blood vessels, which is why it is called a vascular bioregulator (9). Our Khavinson peptides guide covers the family and its evidence.

Vesugen studies: every paper and what it found

Every paper traces to Khavinson’s group or its collaborators. A 2026 single-author review reaches the same conclusion, that efficacy in longevity medicine is unclear because clinical trials and international replication are limited (17). ClinicalTrials.gov lists no registered Vesugen trial (13).

Does Vesugen work for blood vessels?

The vessel evidence is cell work. In cultured endothelium, KED normalized endothelin-1 that rises in atherosclerosis and restenosis, restored connexin expression and raised sirtuin-1 (5). A 2022 review from the same group links KED to inflammaging markers in cardiovascular cells (18). No controlled human study of blood-vessel outcomes turned up.

How might Vesugen work?

Khavinson’s group proposes that short peptides act on DNA or on the proteins around it. For Vesugen, molecular docking placed it on the MKI67 core promoter, the gene for Ki-67, through the sequence CATC (4). That is a simulation and a hypothesis. The 2024 neuron paper states that KED may act through histone proteins or the nucleosome, and that these peptides affect genes tied to dendrite growth but not mitochondrial or lysosomal genes (9).

Does Vesugen grow neurons?

In a lab model, yes, for dendrites. Researchers turned skin fibroblasts from elderly donors into cortical neurons and treated them with KED at 10 µg/mL for 10 days. Primary dendrites rose 32% and total dendrite length rose 42% (9). The same work found no significant change in mitochondria, lysosomes or the senescence marker p16, so it didn’t show KED repairs aging neurons in general.

Earlier mouse work was weaker. KED raised mushroom spines by 20% in mouse neurons under amyloid stress, against 71% for EDR (6), and it only tended to raise neuroplasticity in Alzheimer’s mice (7). Nobody has tested whether any of this reaches the human brain.

Vesugen vs Pinealon, Epitalon and Cardiogen

Vesugen dosage: is there one?

No dose is established. The studies used cell concentrations and mouse injections, and the only human study was a 32-patient report in which Vesugen and Pinealon were tested together (11). Seller schedules don’t come from independent trials.

Vesugen safety and side effects

No adequate safety trials exist. The signals that have been reported:

• Prooxidant activity and fewer CD34+ cells in the 32-patient study, read by the authors as inhibited blood-cell formation (11).
• A narrow safety claim. The same abstract calls the peptides “safe on nuclear genetic level” because chromatin condensation didn’t change. It measured one thing and says the property needs more study (11).
• No toxicology, pharmacokinetic or interaction data turned up.
• Product quality. Gray-market vials vary, and a mislabeled KED vial wastes the experiment.

People with a current or past cancer, pregnant or breastfeeding women, and tested athletes should avoid it.

Is Vesugen approved or legal?

No. FDA hasn’t approved Vesugen, and it doesn’t appear on FDA’s list of bulk substances that may present significant safety risks (14). HHS’s 28 October 2026 interim policy covers six other peptides and excludes research chemicals and supplements (15). WADA’s 2026 List bans any substance without regulatory approval under S0 (16).

How to check a Vesugen vial

Neither SwissChems nor Nextchems lists Vesugen, so hold any seller you find to this checklist.

• Identity by mass spectrometry. KED is 390.4 g/mol by calculation. The look-alike EDR (Pinealon) swaps lysine for arginine and is 418.4, so the two are easy to tell apart on a certificate.
• The right CAS number. 204271-66-9 is the free acid of Lys-Glu-Asp (12). A different end group would carry a different number.
• Measured content in milligrams, a lot number matching your vial and a named laboratory.

Our guide to verifying a peptide COA explains each line, and best peptide vendors compares sellers by what their lab reports show.

Vesugen FAQ

Keep researching: the Khavinson peptides guide, Pinealon, Pancragen, the full list of peptides and bioregulator capsules.

References